Literature DB >> 23911875

Histologic remission: the ultimate therapeutic goal in ulcerative colitis?

Laurent Peyrin-Biroulet1, Aude Bressenot2, Wendy Kampman3.   

Abstract

Ulcerative colitis (UC) is a disease of the mucosal layer, and activity of the disease is assumed to be related to mucosal appearance. Mucosal healing has emerged as a major therapeutic goal in UC. Whether mucosal healing should be the ultimate therapeutic goal in these patients is unknown. Even when endoscopy suggests mucosal healing, evidence of histologic activity has been observed. Histologic healing requires complete recovery of the colonic mucosa, with absence of inflammation or structural changes. Histologic improvements have been linked with improved clinical outcomes, such as a reduced risk of relapse and need for surgery/hospitalization and a reduced risk of developing cancer. Hence, there is a rationale for aiming for histologic remission in UC. Numerous methods of classification of histologic activity in UC have been proposed, although only some of these are widely used. We review the current definitions of histologic remission, the range of scoring systems most commonly used, and the evidence of histologic improvement that is available from the latest therapies for UC. We also highlight questions that will require careful consideration if histologic remission is to become more widely used as an end point in clinical trials and a treatment goal in clinical practice.
Copyright © 2014 AGA Institute. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Disease Modification; Histologic Assessment; Inflammatory Bowel Disease

Mesh:

Year:  2013        PMID: 23911875     DOI: 10.1016/j.cgh.2013.07.022

Source DB:  PubMed          Journal:  Clin Gastroenterol Hepatol        ISSN: 1542-3565            Impact factor:   11.382


  39 in total

1.  Follow-Up of Patients With Ulcerative Colitis and Histological Normalization.

Authors:  Amanda Israel; Britt Christensen; Katia El Jurdi; Victoria Rai; Jacob E Ollech; Russell D Cohen; Atsushi Sakuraba; Sushila R Dalal; David T Rubin
Journal:  Clin Gastroenterol Hepatol       Date:  2019-06-20       Impact factor: 11.382

Review 2.  Mucosal Healing in Ulcerative Colitis: A Comprehensive Review.

Authors:  Pedro Boal Carvalho; José Cotter
Journal:  Drugs       Date:  2017-02       Impact factor: 9.546

Review 3.  "Mucosal healing" in ulcerative colitis: Between clinical evidence and market suggestion.

Authors:  Cristiano Pagnini; Francesca Menasci; Stefano Festa; Gianenrico Rizzatti; Gianfranco Delle Fave
Journal:  World J Gastrointest Pathophysiol       Date:  2014-05-15

4.  Advances in the treatment of ulcerative colitis.

Authors:  Laurent Peyrin-Biroulet
Journal:  Gastroenterol Hepatol (N Y)       Date:  2013-12

5.  Rate and Predictors of Mucosal Healing in Ulcerative Colitis Treated with Thiopurines: Results of a Multicentric Cohort Study.

Authors:  Caroline Prieux-Klotz; Stéphane Nahon; Aurelien Amiot; Leila Sinayoko; Carole Galéano-Cassaz; Stanislas Chaussade; Romain Coriat; Pierre Lahmek; Vered Abitbol
Journal:  Dig Dis Sci       Date:  2016-11-16       Impact factor: 3.199

6.  Histology Grade Is Independently Associated With Relapse Risk in Patients With Ulcerative Colitis in Clinical Remission: A Prospective Study.

Authors:  Talia Zenlea; Eric U Yee; Laura Rosenberg; Marie Boyle; Kavinderjit S Nanda; Jacqueline L Wolf; Kenneth R Falchuk; Adam S Cheifetz; Jeffrey D Goldsmith; Alan C Moss
Journal:  Am J Gastroenterol       Date:  2016-03-15       Impact factor: 10.864

Review 7.  Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): Determining Therapeutic Goals for Treat-to-Target.

Authors:  L Peyrin-Biroulet; W Sandborn; B E Sands; W Reinisch; W Bemelman; R V Bryant; G D'Haens; I Dotan; M Dubinsky; B Feagan; G Fiorino; R Gearry; S Krishnareddy; P L Lakatos; E V Loftus; P Marteau; P Munkholm; T B Murdoch; I Ordás; R Panaccione; R H Riddell; J Ruel; D T Rubin; M Samaan; C A Siegel; M S Silverberg; J Stoker; S Schreiber; S Travis; G Van Assche; S Danese; J Panes; G Bouguen; S O'Donnell; B Pariente; S Winer; S Hanauer; J-F Colombel
Journal:  Am J Gastroenterol       Date:  2015-08-25       Impact factor: 10.864

8.  Clinical Activity and Quality of Life Indices Are Valid Across Ulcerative Colitis But Not Crohn's Disease Phenotypes.

Authors:  Sasha Taleban; Kathleen O Stewart; Darrick K Li; Prashant Singh; Darrell S Pardi; Holly C Sturgeon; Vijay Yajnik; Ramnik J Xavier; Ashwin N Ananthakrishnan; Hamed Khalili
Journal:  Dig Dis Sci       Date:  2016-05-03       Impact factor: 3.199

9.  Efficacy and safety of prolonged release budesonide granules in mesalazine-refractory ulcerative colitis: A multi-centre Phase IIa study (TOPICAL-1).

Authors:  Klaus Fellermann; Ingolf Schiefke; István Rácz; Jelena Derova; Laimas Jonaitis; Sarah Wehrum; Tanju Nacak; Roland Greinwald
Journal:  United European Gastroenterol J       Date:  2020-10-07       Impact factor: 4.623

10.  The prognostic value of histology in ulcerative colitis in clinical remission with mesalazine.

Authors:  Giuseppe Frieri; Brigida Galletti; Mirko Di Ruscio; Rachele Tittoni; Annalisa Capannolo; Donatella Serva; Giovanni Latella; Laura Sollima; Pietro Leocata; Stefano Necozione; Rosamarie Frieri; Angelo Viscido
Journal:  Therap Adv Gastroenterol       Date:  2017-08-25       Impact factor: 4.409

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.